Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX7 | Q99572 | 10/20 | 0.36 |
| ▸ | TNKS | O95271 | 3/20 | 0.36 |
| ▸ | TNKS2 | Q9H2K2 | 3/20 | 0.36 |
| ▸ | P2RY12 | Q9H244 | 1/20 | 0.35 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 2/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | PDE5A | O76074 | 1/20 | 0.32 |
| ▸ | MAOA | P21397 | 1/20 | 0.31 |
| ▸ | MAOB | P27338 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30995420 | 1.00 | P2RX7 (0.36) | P2RX7TNKSTNKS2P2RY12KCNH2 | |
| SCHEMBL30995379 | 0.84 | GPR119 (0.37) | SMN1; SMN2 | |
| SCHEMBL29319793 | 0.84 | GPR119 (0.37) | SMN1; SMN2 | |
| SCHEMBL29318715 | 0.78 | P2RX7 (0.40) | P2RX7P2RY12KCNH2MAOB | |
| SCHEMBL30995282 | 0.78 | P2RX7 (0.40) | P2RX7P2RY12KCNH2MAOB | |
| SCHEMBL27213785 | 0.77 | P2RX7 (0.40) | P2RX7P2RY12KCNH2SMN1; SMN2 | |
| SCHEMBL27391240 | 0.77 | P2RX7 (0.40) | P2RX7P2RY12KCNH2SMN1; SMN2 | |
| SCHEMBL29318403 | 0.76 | PDE5A (0.33) | PDE5A | |
| SCHEMBL27213705 | 0.76 | PDE5A (0.33) | PDE5A | |
| SCHEMBL29317993 | 0.76 | P2RX7 (0.39) | P2RX7P2RY12KCNH2POLBSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240238425-A1 | HSD17B13 Inhibitors and/or Degraders | PFIZER INC. (US) | 2024-07-18 | — | — | US | disclosed |
| US-20240238425-A1 | HSD17B13 Inhibitors and/or Degraders | PFIZER INC. (US) | 2024-07-18 | — | — | US | disclosed |
| US-20240238425-A1 | HSD17B13 Inhibitors and/or Degraders | PFIZER INC. (US) | 2024-07-18 | — | — | US | disclosed |
| WO-2024127297-A1 | 3-FLUORO-4-HYDROXYBENZMIDE-CONTAINING INHIBITORS AND/OR DEGRADERS AND USES THEREOF | PFIZER INC. (US) | 2024-06-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240238425-A1 | HSD17B13 Inhibitors and/or Degraders | HSD17B13, HSD17B3, HSD17B1 | P2RX7 4636/4885TNKS 2583/4885TNKS2 2711/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.